Wells Fargo’s Alto Neuroscience ANRO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$313K Sell
12,241
-14,062
-53% -$422K ﹤0.01% 4461
2026
Q2
$694K Buy
26,303
+25,513
+3,229% +$590K ﹤0.01% 4375
2026
Q1
$17.8K Buy
790
+25
+3% +$463 ﹤0.01% 5819
2025
Q4
$13.6K Buy
+765
New +$9.6K ﹤0.01% 5885
2025
Q3
– Sell
-351
Closed -$772 – 7449
2025
Q2
$772 Sell
351
-10,886
-97% -$25.9K ﹤0.01% 6335
2025
Q1
$24.3K Buy
11,237
+248
+2% +$888 ﹤0.01% 5645
2024
Q4
$46.5K Buy
10,989
+3,139
+40% +$19.6K ﹤0.01% 5510
2024
Q3
$89.8K Buy
7,850
+4,594
+141% +$56.2K ﹤0.01% 5080
2024
Q2
$34.8K Buy
3,256
+3,191
+4,909% +$41.5K ﹤0.01% 5422
2024
Q1
$998 Buy
+65
New +$1.02K ﹤0.01% 6151

Other funds holding ANRO

Wells Fargo's ANRO Position: Q3 2026 in Review

Wells Fargo reduced its Alto Neuroscience (ANRO) stake by 53% in Q3 2026, selling an estimated $422K and leaving 12,241 shares worth $313K. The position accounts for ﹤0.01% of the portfolio, ranked #4461.

Wells Fargo first reported a position in ANRO in Q1 2024 and has held it in 10 quarters since. The position peaked at $694K in Q2 2026. 116 funds tracked by Wall St. Rank hold ANRO as of Q3 2026.

  • Wells Fargo held 12,241 shares of Alto Neuroscience worth $313K as of Q3 2026.
  • Wells Fargo sold 14,062 Alto Neuroscience shares in Q3 2026, an estimated $422K.
  • Alto Neuroscience made up ﹤0.01% of Wells Fargo's portfolio in Q3 2026, its #4461 holding.
  • Wells Fargo first reported a position in Alto Neuroscience in Q1 2024 and has held it in 10 quarters since.
  • Wells Fargo's Alto Neuroscience position peaked at $694K in Q2 2026.
  • 116 funds tracked by Wall St. Rank held Alto Neuroscience as of Q3 2026.

Based on Wells Fargo's 13F filing for Q3 2026, filed 16 Nov 2026.